IL17A and colitis: In addition, studies have reported that intraperitoneal injection of derivatives of oridonin at 5 mg/kg or 7.5 mg/kg in a mouse colitis model can improve colitis via reducing the expression of Th1/Th17, TNF-α, IFN-γ, and IL-17A and inhibiting the expression of NF-kB (p65), thereby improving colitis [39].